Do analysts prefer CSBR or OABI?

OmniAb has a consensus target price of $3.00, suggesting a potential upside of 47.78%. Given OmniAb's stronger consensus rating and higher possible upside, analysts clearly believe OmniAb is more favorable than Champions Oncology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Champions Oncology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 OmniAb 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Do analysts prefer CSBR or ORGO?

Organogenesis has a consensus target price of $5.75, suggesting a potential upside of 140.59%. Given Organogenesis' stronger consensus rating and higher probable upside, analysts plainly believe Organogenesis is more favorable than Champions Oncology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Champions Oncology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Organogenesis 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts recommend INDP or CSBR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Indaptus Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Champions Oncology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend CSBR or PROF?

Profound Medical has a consensus price target of $12.00, suggesting a potential upside of 65.29%. Given Profound Medical's stronger consensus rating and higher possible upside, analysts plainly believe Profound Medical is more favorable than Champions Oncology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Champions Oncology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Profound Medical 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts recommend CSBR or SRZN?

Surrozen has a consensus target price of $42.00, suggesting a potential upside of 112.87%. Given Surrozen's stronger consensus rating and higher probable upside, analysts clearly believe Surrozen is more favorable than Champions Oncology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Champions Oncology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Surrozen 2 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.50

Live Earnings Conference Call: Champions Oncology will host a live Q4 2026 earnings call on July 27, 2026 at 4:30PM ET. Get details.

Champions Oncology (CSBR) Competitors

$6.13 0.00 (0.00%)

Closing price 07/24/2026 03:57 PM Eastern

Extended Trading

$6.14 +0.01 (+0.24%)

As of 07/24/2026 04:10 PM Eastern

Compare

CSBR vs. OABI, ORGO, INDP, PROF, and SRZN

Should you buy Champions Oncology stock or one of its competitors? MarketBeat compares Champions Oncology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Champions Oncology include OmniAb (OABI), Organogenesis (ORGO), Indaptus Therapeutics (INDP), Profound Medical (PROF), and Surrozen (SRZN). These companies are all part of the "med - drugs" industry.

How does Champions Oncology compare to OmniAb?

Champions Oncology (NASDAQ:CSBR) and OmniAb (NASDAQ:OABI) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability, media sentiment and earnings.

Champions Oncology has a net margin of -3.94% compared to OmniAb's net margin of -187.59%. OmniAb's return on equity of -20.31% beat Champions Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Champions Oncology	-3.94%	-57.31%	-7.51%
OmniAb	-187.59%	-20.31%	-18.10%

Champions Oncology has higher revenue and earnings than OmniAb. Champions Oncology is trading at a lower price-to-earnings ratio than OmniAb, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Champions Oncology	$56.94M	1.50	$4.70M	-$0.16	N/A
OmniAb	$18.67M	15.74	-$64.78M	-$0.46	N/A

41.3% of Champions Oncology shares are owned by institutional investors. Comparatively, 72.1% of OmniAb shares are owned by institutional investors. 46.4% of Champions Oncology shares are owned by insiders. Comparatively, 9.8% of OmniAb shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Champions Oncology has a beta of 0.39, suggesting that its share price is 61% less volatile than the broader market. Comparatively, OmniAb has a beta of 0.43, suggesting that its share price is 57% less volatile than the broader market.

OmniAb has a consensus target price of $3.00, suggesting a potential upside of 47.78%. Given OmniAb's stronger consensus rating and higher possible upside, analysts clearly believe OmniAb is more favorable than Champions Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Champions Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
OmniAb	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Champions Oncology and Champions Oncology both had 1 articles in the media. OmniAb's average media sentiment score of 1.87 beat Champions Oncology's score of 0.78 indicating that OmniAb is being referred to more favorably in the news media.

Company	Overall Sentiment
Champions Oncology	Positive
OmniAb	Very Positive

Summary

OmniAb beats Champions Oncology on 9 of the 15 factors compared between the two stocks.

How does Champions Oncology compare to Organogenesis?

Champions Oncology (NASDAQ:CSBR) and Organogenesis (NASDAQ:ORGO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, institutional ownership, profitability, valuation, dividends, earnings and risk.

Organogenesis has higher revenue and earnings than Champions Oncology. Champions Oncology is trading at a lower price-to-earnings ratio than Organogenesis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Champions Oncology	$56.94M	1.50	$4.70M	-$0.16	N/A
Organogenesis	$564.17M	0.55	$37.03M	-$0.19	N/A

41.3% of Champions Oncology shares are owned by institutional investors. Comparatively, 49.6% of Organogenesis shares are owned by institutional investors. 46.4% of Champions Oncology shares are owned by company insiders. Comparatively, 18.8% of Organogenesis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Organogenesis had 2 more articles in the media than Champions Oncology. MarketBeat recorded 3 mentions for Organogenesis and 1 mentions for Champions Oncology. Organogenesis' average media sentiment score of 1.22 beat Champions Oncology's score of 0.78 indicating that Organogenesis is being referred to more favorably in the news media.

Company	Overall Sentiment
Champions Oncology	Positive
Organogenesis	Positive

Champions Oncology has a beta of 0.39, suggesting that its share price is 61% less volatile than the broader market. Comparatively, Organogenesis has a beta of 1.33, suggesting that its share price is 33% more volatile than the broader market.

Organogenesis has a net margin of -0.84% compared to Champions Oncology's net margin of -3.94%. Organogenesis' return on equity of 9.63% beat Champions Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Champions Oncology	-3.94%	-57.31%	-7.51%
Organogenesis	-0.84%	9.63%	4.76%

Organogenesis has a consensus target price of $5.75, suggesting a potential upside of 140.59%. Given Organogenesis' stronger consensus rating and higher probable upside, analysts plainly believe Organogenesis is more favorable than Champions Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Champions Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Organogenesis	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Organogenesis beats Champions Oncology on 13 of the 16 factors compared between the two stocks.

How does Champions Oncology compare to Indaptus Therapeutics?

Indaptus Therapeutics (NASDAQ:INDP) and Champions Oncology (NASDAQ:CSBR) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, media sentiment, analyst recommendations, institutional ownership, earnings and dividends.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Indaptus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Champions Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Indaptus Therapeutics has a beta of 1.11, indicating that its share price is 11% more volatile than the broader market. Comparatively, Champions Oncology has a beta of 0.39, indicating that its share price is 61% less volatile than the broader market.

7.1% of Indaptus Therapeutics shares are held by institutional investors. Comparatively, 41.3% of Champions Oncology shares are held by institutional investors. 9.9% of Indaptus Therapeutics shares are held by company insiders. Comparatively, 46.4% of Champions Oncology shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Indaptus Therapeutics had 1 more articles in the media than Champions Oncology. MarketBeat recorded 2 mentions for Indaptus Therapeutics and 1 mentions for Champions Oncology. Champions Oncology's average media sentiment score of 0.78 beat Indaptus Therapeutics' score of 0.44 indicating that Champions Oncology is being referred to more favorably in the news media.

Company	Overall Sentiment
Indaptus Therapeutics	Neutral
Champions Oncology	Positive

Indaptus Therapeutics has a net margin of 0.00% compared to Champions Oncology's net margin of -3.94%. Champions Oncology's return on equity of -57.31% beat Indaptus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Indaptus Therapeutics	N/A	-1,030.07%	-299.69%
Champions Oncology	-3.94%	-57.31%	-7.51%

Champions Oncology has higher revenue and earnings than Indaptus Therapeutics. Champions Oncology is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indaptus Therapeutics	N/A	N/A	-$20.85M	-$15.40	N/A
Champions Oncology	$56.94M	1.50	$4.70M	-$0.16	N/A

Summary

Champions Oncology beats Indaptus Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Champions Oncology compare to Profound Medical?

Champions Oncology (NASDAQ:CSBR) and Profound Medical (NASDAQ:PROF) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

41.3% of Champions Oncology shares are held by institutional investors. Comparatively, 47.9% of Profound Medical shares are held by institutional investors. 46.4% of Champions Oncology shares are held by company insiders. Comparatively, 1.5% of Profound Medical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Champions Oncology has higher revenue and earnings than Profound Medical. Champions Oncology is trading at a lower price-to-earnings ratio than Profound Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Champions Oncology	$56.94M	1.50	$4.70M	-$0.16	N/A
Profound Medical	$16.10M	16.39	-$42.57M	-$1.24	N/A

In the previous week, Profound Medical had 2 more articles in the media than Champions Oncology. MarketBeat recorded 3 mentions for Profound Medical and 1 mentions for Champions Oncology. Profound Medical's average media sentiment score of 1.33 beat Champions Oncology's score of 0.78 indicating that Profound Medical is being referred to more favorably in the news media.

Company	Overall Sentiment
Champions Oncology	Positive
Profound Medical	Positive

Champions Oncology has a net margin of -3.94% compared to Profound Medical's net margin of -206.76%. Champions Oncology's return on equity of -57.31% beat Profound Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Champions Oncology	-3.94%	-57.31%	-7.51%
Profound Medical	-206.76%	-78.88%	-64.06%

Profound Medical has a consensus price target of $12.00, suggesting a potential upside of 65.29%. Given Profound Medical's stronger consensus rating and higher possible upside, analysts plainly believe Profound Medical is more favorable than Champions Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Champions Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Profound Medical	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Champions Oncology has a beta of 0.39, meaning that its share price is 61% less volatile than the broader market. Comparatively, Profound Medical has a beta of 0.73, meaning that its share price is 27% less volatile than the broader market.

Summary

Profound Medical beats Champions Oncology on 9 of the 16 factors compared between the two stocks.

How does Champions Oncology compare to Surrozen?

Champions Oncology (NASDAQ:CSBR) and Surrozen (NASDAQ:SRZN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations, media sentiment and institutional ownership.

Champions Oncology has a net margin of -3.94% compared to Surrozen's net margin of -4,810.50%. Surrozen's return on equity of 0.00% beat Champions Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Champions Oncology	-3.94%	-57.31%	-7.51%
Surrozen	-4,810.50%	N/A	-154.08%

41.3% of Champions Oncology shares are held by institutional investors. Comparatively, 66.6% of Surrozen shares are held by institutional investors. 46.4% of Champions Oncology shares are held by insiders. Comparatively, 31.7% of Surrozen shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Champions Oncology has higher revenue and earnings than Surrozen. Champions Oncology is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Champions Oncology	$56.94M	1.50	$4.70M	-$0.16	N/A
Surrozen	$3.48M	65.82	-$242.03M	-$37.59	N/A

Champions Oncology has a beta of 0.39, meaning that its share price is 61% less volatile than the broader market. Comparatively, Surrozen has a beta of 0.51, meaning that its share price is 49% less volatile than the broader market.

In the previous week, Surrozen had 2 more articles in the media than Champions Oncology. MarketBeat recorded 3 mentions for Surrozen and 1 mentions for Champions Oncology. Champions Oncology's average media sentiment score of 0.78 beat Surrozen's score of 0.63 indicating that Champions Oncology is being referred to more favorably in the media.

Company	Overall Sentiment
Champions Oncology	Positive
Surrozen	Positive

Surrozen has a consensus target price of $42.00, suggesting a potential upside of 112.87%. Given Surrozen's stronger consensus rating and higher probable upside, analysts clearly believe Surrozen is more favorable than Champions Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Champions Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Surrozen	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.50

Summary

Surrozen beats Champions Oncology on 10 of the 17 factors compared between the two stocks.

Get Champions Oncology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CSBR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CSBR vs. The Competition

Export

Metric	Champions Oncology	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$85.15M	$3.07B	$6.90B	$12.20B
Dividend Yield	N/A	2.07%	2.67%	9.80%
P/E Ratio	-38.31	20.29	27.14	23.63
Price / Sales	1.50	339.70	518.49	88.64
Price / Cash	13.37	26.63	26.39	46.67
Price / Book	22.70	4.13	10.25	6.08
Net Income	$4.70M	$65.94M	$3.60B	$331.70M
7 Day Performance	0.49%	-2.41%	-0.29%	-0.05%
1 Month Performance	-7.54%	-5.87%	-1.77%	-2.63%
1 Year Performance	-1.42%	9.76%	18.23%	13.91%

Champions Oncology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CSBR Champions Oncology	0.4619 of 5 stars	$6.13 flat	N/A	-1.4%	$85.15M	$56.94M	N/A	143	Gap Down
OABI OmniAb	2.1019 of 5 stars	$2.08 -2.8%	$3.00 +44.2%	-3.3%	$309.83M	$18.67M	N/A	7	Positive News
ORGO Organogenesis	1.8973 of 5 stars	$2.49 +6.4%	$5.75 +130.9%	-52.5%	$301.10M	$564.17M	N/A	950
INDP Indaptus Therapeutics	0.39 of 5 stars	$2.82 +7.2%	N/A	-73.7%	$297.83M	N/A	N/A	6	Short Interest Increase Gap Up
PROF Profound Medical	2.1835 of 5 stars	$6.96 -2.0%	$12.00 +72.4%	+27.8%	$258.02M	$18.81M	N/A	150

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CSBR) was last updated on 7/27/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Champions Oncology (CSBR) Competitors

CSBR vs. OABI, ORGO, INDP, PROF, and SRZN

How does Champions Oncology compare to OmniAb?

Summary

How does Champions Oncology compare to Organogenesis?

Summary

How does Champions Oncology compare to Indaptus Therapeutics?

Summary

How does Champions Oncology compare to Profound Medical?

Summary

How does Champions Oncology compare to Surrozen?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CSBR vs. The Competition

Champions Oncology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Champions Oncology (CSBR) Competitors

CSBR vs. OABI, ORGO, INDP, PROF, and SRZN

How does Champions Oncology compare to OmniAb?

Is CSBR or OABI more profitable?

Which has stronger valuation and earnings, CSBR or OABI?

Do insiders & institutionals have more ownership in CSBR or OABI?

Which has more risk and volatility, CSBR or OABI?

Do analysts prefer CSBR or OABI?

Does the media refer more to CSBR or OABI?

Summary

How does Champions Oncology compare to Organogenesis?

Which has better earnings & valuation, CSBR or ORGO?

Do institutionals and insiders have more ownership in CSBR or ORGO?

Does the media refer more to CSBR or ORGO?

Which has more risk & volatility, CSBR or ORGO?

Is CSBR or ORGO more profitable?

Do analysts prefer CSBR or ORGO?

Summary

How does Champions Oncology compare to Indaptus Therapeutics?

Do analysts recommend INDP or CSBR?

Which has more volatility and risk, INDP or CSBR?

Do institutionals & insiders have more ownership in INDP or CSBR?

Does the media prefer INDP or CSBR?

Is INDP or CSBR more profitable?

Which has preferable earnings & valuation, INDP or CSBR?

Summary

How does Champions Oncology compare to Profound Medical?

Do insiders & institutionals hold more shares of CSBR or PROF?

Which has higher valuation & earnings, CSBR or PROF?

Does the media refer more to CSBR or PROF?

Is CSBR or PROF more profitable?

Do analysts recommend CSBR or PROF?

Which has more risk & volatility, CSBR or PROF?

Summary

How does Champions Oncology compare to Surrozen?

Is CSBR or SRZN more profitable?

Do institutionals and insiders hold more shares of CSBR or SRZN?

Which has preferable valuation and earnings, CSBR or SRZN?

Which has more volatility & risk, CSBR or SRZN?

Does the media refer more to CSBR or SRZN?

Do analysts recommend CSBR or SRZN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CSBR vs. The Competition

Champions Oncology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools